Navigation Links
FDA Approves New Drug to Fight Advanced Prostate Cancer
Date:5/15/2013

WEDNESDAY, May 15 (HealthDay News) -- The U.S. Food and Drug Administration announced Wednesday that it has approved a drug to help men with advanced prostate cancer whose disease has spread to the bones.

The drug, Xofigo, is targeted to patients with late-stage, metastatic disease that has spread to the bones but not to other organs, the FDA said in a news release. It is meant for patients who have already undergone surgery and/or drug therapies such as hormone-based treatments.

The FDA said Xofigo, marketed by Wayne, N.J.-based Bayer Pharmaceuticals, was approved more than three months ahead of the original August 2013 deadline the agency had set for a complete review. Instead, the drug was reviewed under the agency's "priority" review program, designated for medicines that appear safe and effective in a context where no good alternative therapy exists.

"Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, explained in the news release.

In a clinical trial involving more than 800 men with symptomatic prostate cancer that was resistant to hormonal therapy and had spread to the bones, men on Xofigo survived a median of 14 months compared to a little over 11 months for men taking a placebo. Side effects from Xofigo included nausea, diarrhea, vomiting and swelling of the legs and feet. Low levels of red and white blood cells, as well as platelets, were also reported among some patients taking Xofigo, the FDA said.

Pazdur noted that "Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer." The other drug, Xtandi, was approved by the FDA last August for men with hormone treatmen
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. FDA Approves Morning-After Pill Without a Prescription
2. FDA Approves New “Gummy Bear” Breast Implants, But Albany Plastic Surgeon Urges Caution
3. FDA Approves 1st in New Class of Type 2 Diabetes Drugs
4. FDA Approves New Multiple Sclerosis Drug
5. FDA Approves Drug for Older Women Experiencing Painful Sex
6. FDA Approves Bionic Eye to Help Against Rare Vision Disorder
7. MSSD Approves of the Encinitas School District’s Holistic Education
8. FDA Approves 3 New Drugs for Type 2 Diabetes
9. FDA Approves 1st Skin Patch to Combat Migraines
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves New Type of Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves New Drug to Fight Advanced Prostate Cancer
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major ... product a mere 8 months after company startup. Its ... glycan release enzyme used in the “Biologics” industry for ... for tissue pathology on Mass Spec devices. PRIME™ is ... North American market (PNGase F PRIMETM). N-Zyme is ...
(Date:9/17/2014)... Recently, BambooIndustry.com, an outstanding company in the ... floorings . There are more than 1000 items in this ... big promotion for these useful items. Each of them is ... , “We are very proud to unveil the new ... these items are made with natural materials by experienced workers. ...
(Date:9/17/2014)... 18, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has released its 2014 ... the firm has launched a big sale for these ... available at deeply discounted rates, from 15 to 65 ... company insists on using comfortable to wear materials. Its ...
(Date:9/17/2014)... September 18, 2014 Dr. Shalev is a ... to Houston to study at the University of Texas, and ... studying she realized her real passion lay in dentistry, and ... from the University of Texas Health Science Center at Houston ... and is a member of The Greater Houston Dental Society, ...
(Date:9/17/2014)... 18, 2014 The National Resident Matching ... , a comprehensive analysis of the relationship between unique ... specialty. The new edition is based on the ... for U.S. allopathic medical school senior students and all ... able to provide this new edition of Charting Outcomes ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3
... 5 (HealthDay News) -- Giving antibiotics to pregnant women at ... newborns, according to a new study. Use of antibiotics ... and should also be used in developing countries, at least ... Edmond, of the London School of Hygiene and Tropical Medicine ...
... WASHINGTONThe rezoning around a planned light rail line in the ... the health of the people in the communities it would ... today by PolicyLink, TakeAction Minnesota, and ISAIAH, a nonprofit coalition ... Paul and St. Cloud region. The HIA was made possible ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- A vaccine ... severe liver damage and even liver cancer, might be possible ... , There is currently no vaccine for hepatitis C, which ... HIV, the hepatitis C virus mutates easily and has always ...
... HealthDay Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- ... United States in recent years are charted in a new report. ... by 1.8 percent a year in men and 1.6 percent a ... And from 1990 through 2008, death rates plunged almost 23 percent ...
... quality of life higher in cancer survivors who exercise, ... though most doctors recommend exercise, many patients fail ... University of Colorado Cancer Center, recently published in the ... by the American College of Sports Medicine, makes planning ...
... The rotovirus vaccine was pulled from the marketplace in ... the updated rotavirus vaccines do not appear to increase ... to a new study by child health experts at ... of the vaccine,re-introduced in 2006 and 2008, prevent infection ...
Cached Medicine News:Health News:Antibiotics in Pregnancy May Shield Newborns From Strep B 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 3Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3Health News:Cancer Incidence, Death Rates Continue to Drop: Report 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 3Health News:Downloadable tool helps cancer survivors plan and monitor exercise 2Health News:U-M study shows updated rotavirus vaccine not linked to increase in bowel obstruction 2
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new report, "Germany ... market data on the Germany Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... SANTA MONICA, Calif. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... who is at the White House today for National ... Proposition 46 that consumer advocates released today. Consumer advocates ... woman who spoke out after losing her ... later discovering that the doctor had a history of ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3